A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomasSeung Ju Kim, Woo Seob Kim, Jin Sung Kim et al.|Annals of Oncology|2016Cited by 54